- Sep 29, 2022TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)
- Feb 1, 2022TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
- Dec 1, 2020TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
- Sep 29, 2020TearClear Appoints Robert Bailey to Board of Directors
- Aug 11, 2020TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development
- May 20, 2020TearClear appoints Dr. Amir Shojaei Chief Development Officer
- Apr 15, 2020TearClear appoints Robert J. Dempsey Chief Executive Officer